RESULTS OF A COLLABORATIVE STUDY FOR FIBRINOGEN MEASUREMENT - EVIDENCE THAT THE USE OF A COMMON CALIBRATOR IMPROVES INTERLABORATORY AGREEMENT

被引:16
作者
CHANTARANGKUL, V
TRIPODI, A
MANNUCCI, PM
机构
[1] MAGGIORE HOSP,IRCCS,INST INTERNAL MED,ANGELO BIANCHI BONOMI HEMOPHILIA & THROMBOSIS CTR,I-20122 MILAN,ITALY
[2] UNIV MILAN,I-20122 MILAN,ITALY
关键词
FIBRINOGEN ASSAY; INTERLABORATORY AGREEMENT; METHOD CALIBRATION;
D O I
10.1097/00001721-199410000-00013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One hundred and sixty-five laboratories were asked in two different surveys to perform duplicate fibrinogen measurements on the same lyophilized plasmas by their own methods and reagents and two different methods of calibration. The between-laboratory variability, expressed as coefficient of variation (CV), and the extent of between-method and between-reagent differences were taken as a measure of agreement between measurements. It was found that the overall between-laboratory range of CV values was 9-16% and that it could be improved if a common calibrator was used. The improvement was more pronounced for the thrombin time-derived (Clauss) method (average CV reduction 43%) than for the prothrombin time (PT)-derived method (average CV reduction 12%). A satisfactory agreement was found between the PT-derived and the Clauss method for the normal-PT plasma, whereas the PT-derived was slightly higher than the Clauss method for the abnormal-PT plasmas, irrespective of calibration. There were statistically significant between-reagent differences within the Clauss method, which were reduced if the common calibrator was used. In conclusion, the results shows that a system of common calibration for fibrinogen determination improves interlaboratory agreement by reducing the CV and minimizing between-reagent differences, particularly for the Clauss method. The authors recommend manufacturers of reagents to link their calibrators to the International Standard for fibrinogen.
引用
收藏
页码:761 / 766
页数:6
相关论文
共 13 条
[1]  
BOVILL EG, 1993, ARCH PATHOL LAB MED, V117, P58
[2]  
GAFFNEY PJ, 1992, THROMB HAEMOSTASIS, V68, P428
[3]   FIBRINOGEN AND FACTOR-VII IN THE PREDICTION OF CORONARY RISK - RESULTS FROM THE PROCAM STUDY IN HEALTHY-MEN [J].
HEINRICH, J ;
BALLEISEN, L ;
SCHULTE, H ;
ASSMANN, G ;
VANDELOO, J .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (01) :54-59
[4]  
HOFFMANN JJML, 1988, CLIN CHEM, V34, P2135
[5]   FIBRINOGEN AND RISK OF CARDIOVASCULAR-DISEASE - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
WOLF, PA ;
CASTELLI, WP ;
DAGOSTINO, RB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (09) :1183-1186
[6]   HEMOSTATIC FUNCTION AND ISCHEMIC-HEART-DISEASE - PRINCIPAL RESULTS OF THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
BROZOVIC, M ;
CHAKRABARTI, RR ;
HAINES, AP ;
IMESON, JD ;
MELLOWS, S ;
MILLER, GJ ;
NORTH, WRS ;
STIRLING, Y ;
THOMPSON, SG .
LANCET, 1986, 2 (8506) :533-537
[7]  
PALARETI G, 1991, CLIN CHEM, V37, P714
[8]  
REINJNERSE GLA, 1989, TIJDSCHR NVKC, V14, P122
[9]   METHOD FOR THE DETERMINATION OF FUNCTIONAL (CLOTTABLE) FIBRINOGEN BY THE NEW FAMILY OF ACL COAGULOMETERS [J].
ROSSI, E ;
MONDONICO, P ;
LOMBARDI, A ;
PREDA, L .
THROMBOSIS RESEARCH, 1988, 52 (05) :453-468
[10]  
STEIGSTRA H, 1991, CLIN CHEM, V37, P1196